Free US stock comparative valuation tools and peer analysis to identify mispriced securities and find value opportunities in the market. We help you understand relative value across different metrics and time periods for better investment decisions. Our platform offers peer comparisons, relative valuation, and spread analysis for comprehensive valuation coverage. Find mispriced stocks with our comprehensive valuation tools and expert analysis for smarter investment selection.
As of 2026-04-16, Coherus Oncology Inc. (CHRS) trades at $1.9 per share, marking a 1.06% gain from the previous session’s close. The oncology-focused biotech stock has been trading in a tight range in recent weeks, with well-defined support and resistance levels drawing attention from technical traders. This analysis breaks down the current market context surrounding CHRS, key technical levels to monitor, and potential near-term scenarios based on current price action and sector trends. No recen
Coherus (CHRS) Stock Signal Based Trade (Bullish Momentum) 2026-04-16 - Risk Reward Ratio
CHRS - Stock Analysis
4722 Comments
1006 Likes
1
Stepehn
Active Reader
2 hours ago
This feels like a silent agreement happened.
👍 38
Reply
2
Jaalah
Community Member
5 hours ago
Am I the only one seeing this?
👍 271
Reply
3
Mieke
Loyal User
1 day ago
Would’ve made a different call if I saw this earlier.
👍 134
Reply
4
Casmin
Active Contributor
1 day ago
Really wish I had read this earlier.
👍 125
Reply
5
Kirston
Daily Reader
2 days ago
Broad indices continue to trend higher with manageable risk.
👍 278
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.